Senseonics Holdings Inc (A:SENS)

Business Focus: Medical Equipment, Supplies & Distribution

Mar 08, 2024 08:05 am ET

Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”) in Florence, Italy.

Mar 06, 2024 08:05 am ET

Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.

Feb 29, 2024 04:05 pm ET

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024 04:05 pm ET

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, February 29, 2024.

Feb 12, 2024 07:00 am ET

Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Feb 12, 2024 06:00 am ET

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

The decision is further recognition of Eversense as an important option for people with diabetes

Feb 06, 2024 08:00 am ET

PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care

PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024. Ascensia is the exclusive global distributor of the Ever

Jan 02, 2024 04:05 pm ET

Senseonics Holdings, Inc. Announces Business Updates

Nov 09, 2023 04:05 pm ET

Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results

Nov 09, 2023 08:05 am ET

Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2023 Healthcare Conference, taking place in New York, NY.

Oct 30, 2023 04:05 pm ET

Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release and Conference Call for November 9, 2023 at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, November 9, 2023.

Oct 09, 2023 07:00 am ET

Ascensia Diabetes Care and Senseonics Announce ‘The CGM for Real Life’ Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes

Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have launched a new U.S. advertising and marketing campaign for Eversense® E3 CGM System. ‘The CGM for Real Life’ campaign is designed to significantly drive awareness of Eversense E3 as a unique CGM option that is ideally suited to supporting the everyday lives of people with diabetes. A sample of the new ad

Sep 26, 2023 08:05 am ET

Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the completion of the ENHANCE Pivotal Clinical Study adult cohort following the recently completed 365-day visit for the final study patient.

Sep 14, 2023 08:05 am ET

Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually.

Sep 11, 2023 08:05 am ET

Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules Capital

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into a $50 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The company also announced it drew down $25 million upon the transaction closing.

Aug 10, 2023 04:15 pm ET

Senseonics Holdings, Inc. Reports Second Quarter 2023 Financial Results

Jul 27, 2023 04:05 pm ET

Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, August 10, 2023.

Jul 05, 2023 04:05 pm ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a).

Jun 26, 2023 07:30 am ET

New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today highlighted new clinical data presented at the American Diabetes Association 83rd Scientific Session. Two studies were presented demonstrating the safety and accuracy of the Eversense E3 CGM system.

Jun 02, 2023 07:00 am ET

Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that UnitedHealthcare, the largest health insurance company in the United States, will begin providing coverage for the Eversense E3 CGM System effective July 1, 2023 for people with type 1 and insulin-requiring type 2 diabetes.

May 26, 2023 07:00 am ET

Senseonics to Participate in the Jefferies Healthcare Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.

May 09, 2023 04:05 pm ET

Senseonics Holdings, Inc. Reports First Quarter 2023 Financial Results

Apr 27, 2023 04:05 pm ET

Senseonics Holdings, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 9, 2023, at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2023 financial results after market close on Tuesday, May 9, 2023.

Apr 24, 2023 07:00 am ET

ASCENSIA DIABETES CARE MARKS ONE-YEAR ANNIVERSARY OF US EVERSENSE E3 CGM LAUNCH WITH COMMERCIAL UPDATE AND INNOVATION OUTLOOK

PARSIPPANY, N.J., April 24, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, marks the one-year anniversary of launching Eversense® E3 in the U.S. with a commercial update and outlook on future innovation, as discussed in the recent Eversense CGM Virtual Analyst and Investor Event.

Apr 18, 2023 04:15 pm ET

Senseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the first pediatric study participant has been inserted with Eversense® 365-day system as part of the pivotal ENHANCE clinical trial at the AMCR Institute, a clinical research center focused on pre-diabetes, type 1, type 2 diabetes and obesity, under the direction of Dr. Timothy Bailey.

Apr 05, 2023 08:00 am ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a).

Mar 15, 2023 04:05 pm ET

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 17, 2023 08:00 am ET

Senseonics Holdings, Inc. and PHC Holdings Corporation To Host Joint Eversense CGM Virtual Analyst and Investor Event on March 15, 2023

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a joint virtual analyst and investor event alongside PHC Holdings Corporation, the parent company of Senseonics’ global commercial partner, Ascensia Diabetes Care, on Wednesday, March 15, 2023 at 6:30pm ET.

Jan 05, 2023 05:58 pm ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a).

Nov 09, 2022 04:05 pm ET

Senseonics to Present at the Stifel 2022 Healthcare Conference

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel Healthcare Conference in New York, NY.

Nov 08, 2022 04:05 pm ET

Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results

Nov 03, 2022 08:00 am ET

Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous G

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® blood glucose monitoring (BGM) system portfolio and exclusive distributor of Eversense® CGM Systems, today announced the launch of a collaboration with the Nurse Practitioner Group (NPG), a leader in multidisciplinary health services and medical staffing solutions. The first patient insertion of the

Nov 03, 2022 08:00 am ET

Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous G

First patients have been served, launching the Nurse Practitioner Group partnership to expedite and expand access to the Eversense® E3 CGM

Oct 25, 2022 04:05 pm ET

Senseonics Holdings, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 8, 2022, at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2022 financial results after market close on Tuesday, November 8, 2022.

Oct 06, 2022 08:00 am ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the design and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Sep 07, 2022 04:05 pm ET

Senseonics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Sep 01, 2022 04:10 pm ET

Senseonics Announces CFO Transition

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced its Chief Financial Officer, Nick Tressler, is transitioning from his position, effective September 1, 2022. Rick Sullivan, Senseonics' current Vice President of Finance, has been appointed to succeed Mr. Tressler as Chief Financial Officer of Senseonics. Mr. Tressler will remain with Senseonics in a supporting role through the end of the year to ensure an orderl

Aug 17, 2022 04:05 pm ET

Senseonics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Showcase, taking place virtually. Management is scheduled to present on Wednesday, August 31, 2022 at 3:00pm ET.

Aug 09, 2022 04:05 pm ET

Senseonics Holdings, Inc. Reports Second Quarter 2022 Financial Results

Aug 04, 2022 08:30 am ET

Thinking about buying stock in Exicure, Yellow Corp, Senseonics, Global Blood Therapeutics, or Motus GI?

NEW YORK, Aug. 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XCUR, YELL, SENS, GBT, and MOTS.

Aug 03, 2022 07:00 am ET

Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Anthem is providing coverage for implantable CGM, which includes the Eversense® CGM System. Anthem’s decision will add more than 45 million covered lives for the long-term implantable CGM system to help manage their diabetes. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies that now

Jul 26, 2022 04:05 pm ET

Senseonics Holdings, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 9, 2022, at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2022 financial results after market close on Tuesday, August 9, 2022.

Jul 05, 2022 04:44 pm ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Jun 16, 2022 06:30 am ET

Senseonics Announces CE Mark Approval of the Eversense E3 Continuous Glucose Monitoring System

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has received CE Mark approval for the next-generation Eversense® E3 CGM System, the longest-lasting system available, with exceptional accuracy. The CE Mark approval confirms that the Eversense E3 meets the requirements of the European Medical Device Regulation (MDR), and enables the commercialization of Eversense E3 in European Union (EU) member countries

May 26, 2022 04:05 pm ET

Senseonics to Participate in the Jefferies Healthcare Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.

May 16, 2022 04:05 pm ET

Senseonics to Participate in the H.C. Wainwright Global Investment Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming hybrid H.C. Wainwright Global Investment Conference.

May 10, 2022 04:05 pm ET

Senseonics Holdings, Inc. Reports First Quarter 2022 Financial Results

Apr 26, 2022 04:05 pm ET

Senseonics Holdings, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 10, 2022, at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2022 financial results after market close on Tuesday, May 10, 2022.

Apr 06, 2022 04:34 pm ET

Senseonics Announces the First Patient Implant of the Eversense E3 CGM System in the U.S.

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, its commercialization partner, have announced the first commercial patient has been implanted with Eversense® E3, kicking off the launch of the next-generation CGM System in the U.S. The Eversense E3 Sensor was approved by the FDA in February and is the longest lasting CGM available in the U.S.

Apr 01, 2022 07:45 pm ET

Senseonics Announces Equity Grants to Employees Under Inducement Plan

Mar 01, 2022 04:05 pm ET

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

Feb 22, 2022 09:50 am ET

Thinking about buying stock in Palantir Technologies, Macy's, Digital World Acquisition, CSX Corp, or Senseonics?

NEW YORK, Feb. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, M, DWAC, CSX, and SENS.

Feb 15, 2022 04:05 pm ET

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for March 1, 2022, at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Tuesday, March 1, 2022.

Feb 15, 2022 09:45 am ET

Thinking about buying stock in Moneygram, Kaival Brands, Senseonics, BP, or Cinedigm?

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGI, KAVL, SENS, BP, and CIDM.

Feb 14, 2022 09:50 am ET

Thinking about buying stock in Motus GI, Peabody Energy, Senseonics, Goodyear Tire & Rubber, or Barrick Gold?

NEW YORK, Feb. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MOTS, BTU, SENS, GT, and GOLD.

Feb 14, 2022 06:00 am ET

ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS

PARSIPPANY, N.J., Feb. 14, 2022 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces that its partner Senseonics Holdings, Inc. (NYSE American: SENS) has received approval from the U.S. Food and Drug Administration (FDA) for the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System. Ascensia plans to make the Eversense E3 sensor, which can be used for up to 6 months, available to patients in the U.S. during the second quarter of 2022.

Feb 11, 2022 09:50 am ET

Thinking about buying stock in Senseonics, ProQR Therapeutics, Surgalign, Astra Space, or Under Armour?

NEW YORK, Feb. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SENS, PRQR, SRGA, ASTR, and UAA.

Feb 11, 2022 07:00 am ET

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months; Provides 2022 Business Outlook

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the approval of the next-generation Eversense® E3 CGM System by the Food and Drug Administration (FDA). The Eversense E3, including proprietary sacrificial boronic acid (SBA) technology to extend longevity to 6 months, is planned to be available to patients in the U.S. through Ascensia Diabetes Care, Senseonics’ global commercial partner, beginning in the second

Feb 07, 2022 07:30 am ET

Thinking about buying stock in Spirit Airlines, Bitfarms, HIVE Blockchain, Bit Digital, or Senseonics?

NEW YORK, Feb. 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAVE, BITF, HIVE, BTBT, and SENS.

Jan 05, 2022 08:00 am ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Jan 05, 2022 07:30 am ET

Thinking about buying stock in Longeveron, Senseonics, Connect Biopharma, Wejo Group, or Energous Corp?

NEW YORK, Jan. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LGVN, SENS, CNTB, WEJO, and WATT.

Jan 04, 2022 04:45 pm ET

Senseonics Announces Business Updates

Dec 21, 2021 08:00 am ET

Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense® NOW Remote Monitoring App for the Android Operating System. The Eversense NOW iOS platform has previously been approved and is currently available in Europe.

Nov 09, 2021 04:05 pm ET

Senseonics Holdings, Inc. Reports Third Quarter 2021 Financial Results

Nov 08, 2021 04:05 pm ET

Senseonics to Participate in Upcoming November Investor Conferences

Oct 26, 2021 04:05 pm ET

Senseonics Holdings, Inc. Schedules Third Quarter 2021 Earnings Release and Conference Call for November 9, 2021, at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021.

Oct 22, 2021 11:05 am ET

Thinking about buying stock in Creatd, Sundial Growers, Progenity, IZEA Worldwide, or Senseonics Holdings?

NEW YORK, Oct. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRTD, SNDL, PROG, IZEA, and SENS.

Oct 21, 2021 08:35 am ET

Thinking about buying stock in Nextplay Technologies, Sio Gene Therapies, Kadmon, Senseonics, or InMed Pharmaceuticals?

NEW YORK, Oct. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NXTP, SIOX, KDMN, SENS, and INM.

Oct 14, 2021 11:00 am ET

Thinking about buying stock in Plug Power, Senseonics, Up Fintech, Waitr Holdings, or Ocugen?

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLUG, SENS, TIGR, WTRH, and OCGN.

Oct 04, 2021 04:05 pm ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Sep 13, 2021 04:05 pm ET

Senseonics Announces a Collaboration with the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, and Ascensia Diabetes Care, the makers of the CONTOUR® family of diabetes blood glucose monitoring devices and commercialization partner for Senseonics, have announced that the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio has begun offering the Eversense® CGM System to its Medicare enrollees effective early September, 2021.

Sep 09, 2021 06:59 pm ET

Senseonics to Participate in the H.C. Wainwright Global Investment Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Investment Conference.

Aug 30, 2021 10:50 am ET

Thinking about buying stock in TAL Education, Newegg, Meta Materials, Zomedica, or Senseonics?

NEW YORK, Aug. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TAL, NEGG, MMAT, ZOM, and SENS.

Aug 23, 2021 10:50 am ET

Thinking about buying stock in Endo International, Nio, New Oriental Education, Tencent Music Entertainment, or Senseonics?

NEW YORK, Aug. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, NIO, EDU, TME, and SENS.

Aug 20, 2021 09:31 am ET

Thinking about buying stock in 360 DigiTech, CohBar, Buckle, Amyris, or Senseonics?

NEW YORK, Aug. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QFIN, CWBR, BKE, AMRS, and SENS.

Aug 19, 2021 08:30 am ET

Thinking about buying stock in Coherus Biosciences, Macy's, Salarius Pharmaceuticals, Verb Technology, or Senseonics?

NEW YORK, Aug. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHRS, M, SLRX, VERB, and SENS.

Aug 09, 2021 04:05 pm ET

Senseonics Holdings, Inc. Reports Second Quarter 2021 Financial Results

Jul 26, 2021 04:05 pm ET

Senseonics Holdings, Inc. Schedules Second Quarter 2021 Earnings Release and Conference Call for August 9, 2021, at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2021 financial results after market close on Monday, August 9, 2021.

Jul 02, 2021 04:05 pm ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Jun 28, 2021 09:31 am ET

Thinking about buying stock in Iterum Therapeutics, Kymera Therapeutics, Senseonics, Avrobio, or ChemoCentryx?

NEW YORK, June 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITRM, KYMR, SENS, AVRO, and CCXI.

Jun 28, 2021 08:00 am ET

Senseonics Announces Presentation of PROMISE Data at the American Diabetes Association 81st Scientific Sessions

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.

Jun 22, 2021 10:45 am ET

Thinking about buying stock in Torchlight Energy, Globalstar, MediciNova, Senseonics, or Clean Energy Fuels?

NEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRCH, GSAT, MNOV, SENS, and CLNE.

Jun 21, 2021 10:55 am ET

Thinking about buying stock in Senseonics, Clean Energy Fuels, Orphazyme, Xpeng, or Amarin Corp?

NEW YORK, June 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SENS, CLNE, ORPH, XPEV, and AMRN.

Jun 16, 2021 10:50 am ET

Thinking about buying stock in ContextLogic, Senseonics, BlackBerry, Seanergy Maritime, or Citius Pharmaceuticals?

NEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, SENS, BB, SHIP, and CTXR.

Jun 15, 2021 10:50 am ET

Thinking about buying stock in Torchlight Energy, Senseonics, Can Fite Biopharma, EHang Holdings, or Luckin Coffee?

NEW YORK, June 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRCH, SENS, CANF, EH, and LKNCY.

Jun 14, 2021 08:30 am ET

Thinking about buying stock in Orphazyme, Corsair Gaming, Senseonics, Vaxart, or Anavex Life Sciences?

NEW YORK, June 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORPH, CRSR, SENS, VXRT, and AVXL.

Jun 11, 2021 08:30 am ET

Thinking about buying stock in Novan, Chemomab Therapeutics, Precigen, ChemoCentryx, or Senseonics?

NEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, CMMB, PGEN, CCXI, and SENS.

Jun 09, 2021 11:00 am ET

Thinking about buying stock in Ashford Hospitality Trust, Lordstown Motors, Nokia, Adamis Pharmaceuticals, or Senseonics?

Jun 03, 2021 04:05 pm ET

Senseonics Announces Results of the PROMISE Study Demonstrating Strong Accuracy of 180 Day CGM Sensor

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the PROMISE Study evaluating the accuracy and safety of the next generation Eversense CGM System for up to 180 days with reduced calibrations. The data was presented by Satish Garg, MD, Professor of Medicine at the Barbara Davis Center of the University of Colorado, Denver, and the study group Principal Investigator (PI),

May 13, 2021 04:05 pm ET

Senseonics Holdings, Inc. Reports First Quarter 2021 Financial Results

Apr 29, 2021 04:05 pm ET

Senseonics Holdings, Inc. Schedules First Quarter 2021 Earnings Release and Conference Call for May 13, 2021 at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13, 2021.

Apr 01, 2021 07:55 pm ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Mar 04, 2021 04:05 pm ET

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 02, 2021 05:29 pm ET

Senseonics to Participate in the H.C. Wainwright Global Life Sciences Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Life Sciences Conference.

Feb 19, 2021 08:00 am ET

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for March 4, 2021 at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4, 2021.

Feb 11, 2021 04:05 pm ET

Senseonics to Participate in the SVB Leerink Global Healthcare Conference

Feb 09, 2021 09:50 am ET

Thinking about buying stock in Sundial Growers, Zomedica, AMC Entertainment, Senseonics, or Nokia?

NEW YORK, Feb. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, ZOM, AMC, SENS, and NOK.

Feb 08, 2021 08:31 am ET

Thinking about buying stock in Zomedica, Sundial Growers, Senseonics Holdings, Phunware, or Zynerba Pharmaceuticals?

NEW YORK, Feb. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, SNDL, SENS, PHUN, and ZYNE.

Feb 05, 2021 10:00 am ET

Thinking about buying stock in Zomedica, Nokia, Zynerba Pharmaceuticals, Senseonics Holdings, or Atossa Therapeutics?

NEW YORK, Feb. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, NOK, ZYNE, SENS, and ATOS.

Feb 01, 2021 08:00 am ET

Senseonics Announces Initiation of European Commercial Efforts by Partner Ascensia Diabetes Care

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Ascensia Diabetes Care (Ascensia) has commenced sales and marketing activities for the Eversense® XL CGM system in key European markets as of today, as part of their strategic partnership announced in August, 2020.

Jan 28, 2021 11:33 pm ET

Senseonics Holdings Announces Closing of $115.0 Million Bought Deal Offering of Common Stock and Full Exercise of the Option to Purchase Additional Shares

Senseonics Holdings, Inc. (NYSE American: SENS) (“Senseonics” or the “Company”), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the closing on January 26, 2021, of its previously announced public underwritten offering of 59,740,259 shares of common stock of the Company, including the exercise in full by the underwriter of its option to purchase an additional 7,792,207 shares of common stock which closed yesterday, at a public offering price of $1.925 p

Jan 22, 2021 12:18 am ET

Senseonics Holdings Increases Previously Announced Bought Deal Offering of Common Stock to $100.0 Million

Senseonics Holdings, Inc. (NYSE American: SENS) (“Senseonics” or the “Company”), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 51,948,052 shares of common stock of the Company at a public offering price of $1.925 per share, less underwriting discounts and commissions. The Company also has granted the underwr

Jan 21, 2021 05:13 pm ET

Senseonics Holdings Announces $50.0 Million Bought Deal Offering of Common Stock

Senseonics Holdings, Inc. (NYSE American: SENS) (“Senseonics” or the “Company”), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 25,974,026 shares of common stock of the Company at a public offering price of $1.925 per share, less underwriting discounts and commissions. The Company also has granted t

Jan 20, 2021 08:31 am ET

Thinking about buying stock in Zosano Pharma, Senseonics, Tellurian, Cinedigm, or AMC Entertainment?

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, SENS, TELL, CIDM, and AMC.

Jan 19, 2021 08:00 am ET

Senseonics Announces a Positive Coverage Decision for Eversense CGM from EmblemHealth

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, announced today that EmblemHealth is now providing coverage for the Eversense® CGM System, effective immediately. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.

Jan 17, 2021 10:22 pm ET

Senseonics Holdings Announces $50.0 Million Registered Direct Offering of Common Stock

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into securities purchase agreements with several healthcare-focused and other institutional investors to purchase 40,000,000 shares of its common stock in a registered direct offering at a purchase price of $1.25 per share.

Jan 15, 2021 08:31 am ET

Thinking about buying stock in VBI Vaccines, Senseonics Holdings, Aemetis, Applied DNA Sciences, or Aphria?

NEW YORK, Jan. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VBIV, SENS, AMTX, APDN, and APHA.

Jan 06, 2021 04:05 pm ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Dec 24, 2020 07:31 am ET

Thinking about buying stock in Pfizer, Senseonics Holdings, AIM ImmunoTech, Aileron Therapeutics, or Microvision?

NEW YORK, Dec. 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, SENS, AIM, ALRN, and MVIS.

Dec 23, 2020 04:49 pm ET

Senseonics Announces Business Update

Dec 07, 2020 08:31 am ET

Thinking about buying stock in Affimed NV, Kura Oncology, Matinas BioPharma, Uranium Energy, or Senseonics Holdings?

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AFMD, KURA, MTNB, UEC, and SENS.

Nov 09, 2020 04:05 pm ET

Senseonics Holdings, Inc. Reports Third Quarter 2020 Financial Results

Nov 09, 2020 04:04 pm ET

Senseonics Announces Equity Line of Credit Financing Agreement

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced entrance into an equity line of credit financing agreement with current shareholder Energy Capital, LLC for up to $12.0 million.

Nov 05, 2020 04:05 pm ET

Senseonics to Participate in the Credit Suisse Healthcare Conference

Oct 28, 2020 04:05 pm ET

Senseonics Holdings, Inc. Schedules Third Quarter 2020 Earnings Release and Conference Call for November 9, 2020 at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2020 financial results after market close on Monday, November 9, 2020.

Oct 06, 2020 08:30 am ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Oct 05, 2020 07:30 am ET

Senseonics Submits PMA Application for 180-Day Eversense System to the FDA

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the Premarket Approval (PMA) supplement application to extend the wearable life of the Eversense® CGM System to 180 days was submitted to the United States Food and Drug Administration (FDA) on September 30. Summary accuracy results from the PROMISE Clinical Study for the 180-day product were also announced.

Sep 08, 2020 05:30 pm ET

Senseonics Announces Analyst and Investor Event on September 15, 2020

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a virtual analyst and investor event on Tuesday, September 15, 2020 at 4:30pm ET.

Sep 01, 2020 08:00 am ET

Local Coverage Determinations for Implantable CGMs Announced by Three Medicare Administrative Contractors

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that three Medicare Administrative Contractors (MACs) have issued Local Coverage Determinations (LCDs) for the use of implantable CGM systems, such as the Eversense® CGM System. LCDs are policy decisions by MACs establishing services as reasonable, necessary and eligible for payment by Medicare.

Aug 10, 2020 04:07 pm ET

Senseonics Holdings, Inc. Reports Second Quarter 2020 Financial Results

Aug 10, 2020 04:05 pm ET

Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the formation of a strategic partnership with Ascensia Diabetes Care (Ascensia), through a commercialization and collaboration agreement, which will make Ascensia the exclusive worldwide distributor of Senseonics’ Eversense® CGM systems. The company also announced a concurrent financing agreement with PHC Holdings Corporation, the parent company of Ascensia.

Aug 07, 2020 08:00 am ET

Senseonics Announces Positive Coverage Decision for Eversense CGM from Highmark Inc.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced Highmark Inc. will begin providing coverage for the Eversense CGM effective September 28, 2020. This coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.

Aug 03, 2020 04:05 pm ET

Senseonics Holdings, Inc. Schedules Second Quarter 2020 Earnings Release and Conference Call for August 10, 2020 at 4:30 p.m. Eastern Time

Aug 03, 2020 10:30 am ET

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Senseonics Holdings, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Senseonics Holdings, Inc. (NYSE American: SENS).

Jul 02, 2020 04:05 pm ET

Senseonics Announces Equity Grants to Employees Under Inducement Plan

Jun 09, 2020 04:05 pm ET

Senseonics Holdings, Inc. Reports First Quarter 2020 Financial Results

May 28, 2020 04:37 pm ET

Senseonics Holdings, Inc. Schedules First Quarter 2020 Earnings Release and Conference Call for June 9, 2020 at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its first quarter 2020 financial results after market close on Tuesday, June 9, 2020.

May 26, 2020 04:17 pm ET

Senseonics Launches New Remote Monitoring App for Android Users in US

“Now more than ever, the world relies upon remote methods of contact and support,” said Tim Goodnow, PhD, President and CEO of Senseonics. “With the Eversense NOW app, Eversense CGM users can enjoy the added peace of mind that comes with knowing friends and family can remotely view real-time glucose data, see trend graphs, and receive real-time glucose alerts. With the launch of the Android platform, it joins our previously available Eversense NOW iOS platform to provide added support and convenience for our users during these unprecedented times.”

May 14, 2020 09:00 am ET

Local Coverage Determination Proposed for Implantable Continuous Glucose Monitors by Medicare Administrative Contractors

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring system for people with diabetes, announced today that three Medicare Administrative Contractors (MACs), Palmetto, First Coast Service Options (FCSO) and Novitas have removed implantable continuous glucose monitors (CGM) such as Eversense from their non-coverage policy. In addition, FCSO and Novitas have each published proposed Local Coverage Determinations (LCD) for implantable CGMs. This now ena

May 06, 2020 04:05 pm ET

Senseonics Announces Positive Coverage Decision for Eversense CGM from Several Blue Cross Blue Shield Plans

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that three more Blue Cross Blue Shield plans are now providing coverage for the Eversense® CGM System, effective immediately. These recent coverage decisions add to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placeme

Apr 28, 2020 04:15 pm ET

Senseonics Eversense® Sensor Receives MRI Conditional Approval in Europe

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced regulatory approval that the Eversense® XL Sensor is no longer contraindicated for MRI which means that the sensor does NOT need to be removed from under the skin during MRI scanning. During scanning the external Eversense Smart Transmitter must still be removed, and once scanning is completed, the transmitter is easily repositioned on the skin.

Apr 22, 2020 08:11 am ET

Senseonics Enters into New Credit Facilities with Certain Funds Managed by Highbridge Capital Management, LLC

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has entered into a new senior secured Term Loan Agreement with certain funds managed by Highbridge Capital Management, LLC (“Highbridge”), an existing stakeholder. Pursuant to the Term Loan Agreement, the Company will draw down $15.0 million from the new First Lien Secured Term Loan with a maturity date of October 24, 2021 (the “First Lien Term Lo

Apr 03, 2020 04:15 pm ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Mar 23, 2020 08:26 am ET

Senseonics Exploring Strategic Options to Enhance Stakeholder Value

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced that its Board of Directors has decided to explore potential strategic alternatives to enhance stakeholder value. The Company is engaging Moelis & Company, LLC as its financial advisor and Cooley, LLP as its legal advisor.

Mar 12, 2020 04:05 pm ET

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2019.

Mar 04, 2020 04:05 pm ET

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for March 12, 2020 at 4:30 p.m. Eastern Time

Feb 26, 2020 08:30 am ET

Senseonics Announces the FDA Approval to Continue the PROMISE Sensor Clinical Study in an Extended Cohort to 365 Days to Gather Feasibility Data

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the FDA approved a subgroup (with a modified chemistry to enhance longevity) of PROMISE study participants to continue for a total of 365 days to gather feasibility data on the safety and accuracy of a 365-day sensor.

Feb 24, 2020 08:00 am ET

Senseonics Reports at ATTD Glycemic Outcomes Across Adult Age Ranges with Real-World Eversense CGM Use

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for adults with diabetes, presented data that demonstrated real-world use of the Eversense® CGM System across adult age ranges. Key International Consensus1 CGM targets were met in many adult patients with a greater percentage of users in the older age groups achieving targets and the younger adults showing promising results. The oldest age range met CGM target

Feb 18, 2020 08:00 am ET

Senseonics Announces a Positive Coverage Decision for Eversense CGM from Cigna

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Cigna is now providing coverage for the Eversense® CGM System, effective February 15, 2020. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.

Feb 11, 2020 08:00 am ET

Senseonics Announces Partnership with Companion Medical

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system, today announced an agreement with Companion Medical to integrate Eversense® CGM System real-time glucose data with the Companion Medical InPen™ smart system for insulin delivery. For people living with insulin-dependent diabetes, this news means that real-time glucose data will continuously be incorporated into their InPen insulin system allowing for more relevant insulin

Jan 03, 2020 04:05 pm ET

Senseonics Announces Equity Grants to Employees Under Inducement Plan

Dec 02, 2019 04:05 pm ET

Senseonics Launches Eversense CGM System with Non-Adjunctive Claim in the U.S.

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced today that Eversense users who download the new Eversense® CGM mobile app can start dosing insulin based off of the readings from their Eversense System without the need to do a confirmatory blood glucose fingerstick measurement.

Nov 21, 2019 05:22 pm ET

Senseonics Publishes Positive Longitudinal Performance Over Multiple Sensor Insertions and Removal Cycles of the Eversense® CGM System

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced the publication of an assessment of the performance of multiple sequential cycles of Eversense 90 and 180-day CGM System use in the peer reviewed scientific journal Diabetes Technology and Therapeutics. This real-world data of 945 adult users in the home-setting demonstrated that the performance of the sensor over four sensor cycles is stabl

Nov 12, 2019 04:05 pm ET

Senseonics Holdings, Inc. Reports Third Quarter 2019 Financial Results

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the quarter ended September 30, 2019.

Nov 12, 2019 04:03 pm ET

Medicare Establishes National Payment Rate for Eversense® CGM System

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only FDA-approved, long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced today that the Centers for Medicare and Medicaid Services (CMS) finalized a national payment rate for Eversense that was recently published in the calendar year 2020 Physician Fee Schedule Final Rule. The Eversense CGM system will be the first CGM technology to be reimbursed through the Part B Medical Services benefit for Medicare be

Oct 29, 2019 04:05 pm ET

Senseonics Holdings, Inc. Schedules Third Quarter 2019 Earnings Release and Conference Call for November 12, 2019 at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its third quarter 2019 financial results after market close on Tuesday, November 12, 2019.

Oct 24, 2019 06:44 pm ET

Senseonics Announces a Positive Coverage Decision for Eversense CGM From Humana

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Humana is now providing coverage for the Eversense CGM System and insertion procedure, effective October 22, 2019. Under the Humana coverage policy patients with both type 1 diabetes and type 2 diabetes that require insulin are eligible for coverage for Eversense.

Oct 14, 2019 04:05 pm ET

Senseonics Announces a Positive Coverage Decision for Eversense CGM from Health Care Service Corporation - Blue Cross Blue Shield of Illinois, Montana, New Mexico, Oklahoma and Texas

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Health Care Service Corporation (HCSC) - Blue Cross Blue Shield is now providing coverage for the Eversense CGM System, effective October 15, 2019. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office

Oct 01, 2019 04:05 pm ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it has made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a).

Sep 30, 2019 04:05 pm ET

Senseonics Announces the Completion of US Patient Enrollment in the PROMISE 180-Day Sensor Clinical Study

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the completion of patient enrollment in the Eversense PROMISE 180-day sensor Clinical Study.

Sep 03, 2019 04:05 pm ET

Senseonics Announces Two Positive Blue Cross Blue Shield Coverage Decisions for Eversense CGM

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Blue Cross Blue Shield of Massachusetts and Blue Cross Blue Shield of Idaho are now providing coverage for Eversense CGM. These recent coverage decisions add to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.

Aug 27, 2019 04:56 pm ET

Real-World Experience of Repeat Users Shows Long-Term Safety of the Implantable Eversense CGM System in the Home-Use Setting

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced the publication in Diabetes Technology and Therapeutics of the long-term safety data of the Eversense CGM System derived from its commercial experience during the two-year Post Market Clinical Follow Up (PMCF) registry in Europe. The registry data demonstrated Eversense’s safety, with no related serious adverse events and a low rate of rela

Aug 21, 2019 06:00 pm ET

Senseonics Publishes Eversense® CGM Real-World Data from First U.S. Users

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced the publication in Diabetes Technology and Therapeutics of their real-world data from the first 205 U.S. patients using Eversense CGM. The real-world data demonstrated that the Eversense CGM System showed strong performance and safety over a 90-day sensor wear period, especially in the low glucose ranges. This data provides real-world eviden

Aug 07, 2019 04:05 pm ET

Senseonics Holdings, Inc. Reports Second Quarter 2019 Financial Results

Jul 25, 2019 04:05 pm ET

Senseonics to Participate in the Canaccord Genuity Growth Conference

Jul 24, 2019 04:35 pm ET

Senseonics Holdings, Inc. Schedules Second Quarter 2019 Earnings Release and Conference Call for August 7, 2019 at 4:30 p.m. Eastern Time

Jul 18, 2019 05:30 am ET

Senseonics Announces Pricing of $82.0 Million 5.25% Convertible Senior Notes Due 2025

Senseonics Holdings, Inc. (“Senseonics” or the “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of an $82.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 (the “2025 notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The sale of the 2025 notes is expected to close on July 25,

Jul 18, 2019 05:30 am ET

Senseonics Announces Pricing of Public Offering of Common Stock

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of a registered underwritten public offering of 22,727,273 shares of its common stock at a price to the public of $1.10 per share. The gross proceeds from the offering are expected to be $25.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Senseonics. In addition, Senseonics has granted

Jul 16, 2019 04:06 pm ET

Senseonics Announces Commencement of Convertible Notes Offering

Senseonics Holdings, Inc. (“Senseonics” or the “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the commencement of an offering of $80.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 (the “2025 notes”) and the commencement of a consent solicitation in respect of its outstanding 5.25% convertible senior subordinated notes due 2023 (the “2023 notes”).

Jul 16, 2019 04:06 pm ET

Senseonics Announces Public Offering of Common Stock

Senseonics Holdings, Inc. (“Senseonics”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has commenced a registered underwritten public offering of $25.0 million of its shares of common stock. In addition, Senseonics anticipates granting the underwriter a 30-day option to purchase up to an additional $3.75 million of its shares of common stock. All of the shares to be sold in the offering are to be sold by Senseonics. The

Jul 16, 2019 04:05 pm ET

Senseonics Holdings, Inc. Reports Preliminary Second Quarter 2019 Net Revenue

Senseonics Holdings, Inc. (“Senseonics” or “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced preliminary financial results for the second quarter of 2019.

Jul 03, 2019 01:15 pm ET

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Jun 06, 2019 04:36 pm ET

Senseonics Announces FDA Approval for a Non-Adjunctive Indication (Dosing Claim) for the Eversense® 90-day CGM System

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that they received FDA approval for the non-adjunctive indication (dosing claim) for the Eversense Continuous Glucose Monitoring System. Patients will soon be able to use Eversense as a replacement for fingersticks to make diabetes treatment decisions throughout the day. To use the non-adjunctive dosing indication, u

Jun 05, 2019 04:05 pm ET

Senseonics to Present Real-World, Long-Term Safety Data of the First Implantable CGM Sensor at the American Diabetes Association’s 79th Scientific Sessions

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, will present the long-term safety data of the Eversense CGM System derived from its Post Market Clinical Follow Up (PMCF) registry in Europe. The poster is to be presented by Katherine Tweden, PhD on Saturday, June 8 from 11:30 am – 12:30 pm in Hall F of the North Exhibition building during the annual American Diabetes Associa

Jun 04, 2019 04:05 pm ET

Senseonics to Participate in the Raymond James Life Sciences and MedTech Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Raymond James Life Sciences and MedTech Conference in New York, NY.

May 21, 2019 04:05 pm ET

Senseonics to Participate in the Guggenheim MedTech Disruptors Summit

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Guggenheim MedTech Disruptors Summit in New York, NY.

May 09, 2019 04:05 pm ET

Senseonics Holdings, Inc. Reports First Quarter 2019 Financial Results

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the design, development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the quarter ended March 31, 2019.

Apr 25, 2019 04:05 pm ET

Senseonics Holdings, Inc. Schedules First Quarter 2019 Earnings Release and Conference Call for May 9, 2019 at 4:30 p.m. Eastern Time

Apr 12, 2019 07:45 am ET

Report: Exploring Fundamental Drivers Behind Visteon, Senseonics, Concert Pharmaceuticals, Cincinnati Bell, Protagonist Therapeutics, and THL Credit — New Horizons, Emerging Trends, and Upcoming Devel

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Visteon Corporation (NASDAQ:VC), Senseonics Holdings, Inc. (NYSE:SENS),...

Mar 22, 2019 08:00 am ET

Senseonics Launches the Eversense® Bridge Patient Access Program in the U.S.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has announced the launch of the Eversense Bridge Program. Under the program, patients can access the Eversense CGM System, the only long-term CGM that lasts up to 90 days, for only $99* plus the cost of the sensor placement by the healthcare provider.

Mar 12, 2019 04:05 pm ET

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2018.

Mar 06, 2019 08:00 am ET

Senseonics Announces Appointment of Francine R. Kaufman, M.D. as Chief Medical Officer

Mar 05, 2019 08:00 am ET

Senseonics Eversense® CGM Launches Integration with Glooko

Feb 28, 2019 04:05 pm ET

Senseonics to Participate in the Cowen Health Care Conference

Feb 20, 2019 04:05 pm ET

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for March 12, 2019 at 4:30 p.m. Eastern Time

Feb 14, 2019 07:03 pm ET

Senseonics Announces Partnership with Geo-Med to Provide Veterans Access to Eversense CGM

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that it has partnered with Geo-Med, LLC, a verified Service-Disabled Veteran-Owned Small Business (SDVOSB) to provide access to Eversense CGM to more than 9 million covered veterans and U.S. government personnel.

Feb 03, 2019 05:00 pm ET

Senseonics Announces Extension of Distribution Agreement with Roche Diabetes Care

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced an extension of its distribution agreement with Roche Diabetes Care. As extended, the agreement now runs through January 31, 2021. Under terms of the extended agreement, Roche will continue its role as Senseonics exclusive distributor in Europe, the Middle East and Africa, excluding Scandinavia and Israel. In

Jan 30, 2019 07:23 pm ET

Senseonics Eversense CGM Sensor Receives Indication for MRI

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that they received notice from FDA that the Eversense Sensor is no longer contraindicated for MRI scanning*.

Jan 22, 2019 07:40 am ET

Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys — What Drives Growth in Today's Competitive Lan

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Inovalon Holdings, Inc. (NASDAQ:INOV), Merit Medical Systems, Inc....

Jan 07, 2019 04:10 pm ET

Senseonics Appoints Jon D. Isaacson as Chief Financial Officer

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the appointment of Jon D. Isaacson as the company’s Chief Financial Officer, effective immediately. Concurrently, and as previously announced, R. Don Elsey has stepped down from the position and will continue in an advisory role to ensure an orderly transition and completion of the company’s annual SEC filings

Jan 03, 2019 04:45 pm ET

Senseonics Announces First Study Participant Implanted in the U.S. as Part of the PROMISE 180-Day Sensor Clinical Study and the Submission of Key PMA Supplements to the FDA to Advance Current 90-Day P

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the extended life Eversense® XL sensor that lasts up to 180 days has been implanted in the first U.S. study participant as part of the clinical trial for pre-market application submission to the Food and Drug Administration.

Dec 03, 2018 04:37 pm ET

Senseonics Holdings, Inc. Announces Retirement of Chief Financial Officer

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the retirement of Chief Financial Officer, R. Don Elsey. Mr. Elsey has agreed to remain in his current role and to step down when a replacement is appointed. He will then continue with the company in an advisory role to ensure an orderly transition and completion of the company’s annual SEC filings for the 201

Nov 27, 2018 04:05 pm ET

Eversense CGM Wins a 2018 “Best of What’s New” Award

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that the Eversense® Continuous Glucose Monitoring (CGM) System has been awarded one of Popular Science’s 2018 “Best of What’s New” Awards in the Health category.

Nov 12, 2018 08:45 am ET

Report: Exploring Fundamental Drivers Behind Sterling Construction, Tredegar, j2 Global, Medical Transcription Billing, Concert Pharmaceuticals, and Senseonics — New Horizons, Emerging Trends, and Upc

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Sterling Construction Company Inc (NASDAQ:STRL), Tredegar Corporation...

Nov 08, 2018 04:05 pm ET

Senseonics Holdings, Inc. Reports Third Quarter 2018 Financial Results

Nov 06, 2018 10:24 pm ET

Senseonics Announces FDA Approval to Expand Eversense® CGM Certification to Nurse Practitioners and Physician Assistants

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that the Eversense® Continuous Glucose Monitoring (CGM) System has received FDA approval for qualified health care providers to be trained and certified to provide patients with the highly accurate sensor that lasts up to three months. Previously, the sensor insertion and removal procedure could

Oct 22, 2018 04:42 pm ET

Senseonics Announces Aetna’s Positive Coverage Decision for Eversense

Oct 18, 2018 08:30 am ET

New Research Coverage Highlights QuinStreet, Senseonics, Ring Energy, Blue Apron, Second Sight Medical Products, and Real Goods Solar — Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of QuinStreet, Inc. (NASDAQ:QNST), Senseonics Holdings, Inc. (NYSE:SENS),...

Oct 15, 2018 04:05 pm ET

Senseonics Holdings, Inc. Schedules Third Quarter 2018 Earnings Release and Conference Call for November 8, 2018 at 4:30 p.m. Eastern Time

Aug 27, 2018 08:25 am ET

Report: Exploring Fundamental Drivers Behind Hemispherx BioPharma, Express, Senseonics, Forestar Group, CoBiz Financial, and Beacon Roofing Supply — New Horizons, Emerging Trends, and Upcoming Develop

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hemispherx BioPharma, Inc. (NYSE:HEB), Express, Inc. (NYSE:EXPR),...

Aug 08, 2018 04:10 pm ET

Senseonics Holdings, Inc. Reports Second Quarter 2018 Financial Results

Aug 07, 2018 08:53 am ET

Senseonics Begins U.S. Commercialization of Eversense Continuous Glucose Monitoring System With First Shipment, First Users and First Policy Coverage

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the Eversense® CGM System is now available at trained clinics across the U.S. and physicians have begun sensor placements with patients. Concurrently, the company reported that its first commercial payer, Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey, has added coverage

Jul 26, 2018 04:05 pm ET

Senseonics to Participate in the Canaccord Genuity Growth Conference

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced the company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA.

Jul 25, 2018 04:05 pm ET

Senseonics Holdings, Inc. Schedules Second Quarter 2018 Earnings Release and Conference Call for August 8, 2018 at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced that it plans to release its second quarter 2018 financial results after market close on Wednesday, August 8, 2018.

Jul 10, 2018 08:36 am ET

Senseonics & Glooko Announce Partnership on Integrated Diabetes Management

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced a partnership with Glooko, Inc, the leading diabetes data management company. The partnership enables integration of the long-term Eversense® bran

Jun 28, 2018 04:05 pm ET

Senseonics Announces Closing of Public Offering of Common Stock

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares. Total proceeds for the offering were $149.5 million before deducting estimated offe

Jun 26, 2018 07:13 am ET

Senseonics Announces Pricing of Public Offering of Common Stock

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $130.0 million, before deducting estimated offering expenses payable by Senseonics. All of the shares sold in the offering were sold by Senseonics. The offering is expected to close on June 28, 2018, subject

Jun 25, 2018 04:11 pm ET

Senseonics Announces Public Offering of Common Stock

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has commenced a registered underwritten public offering of $80 million of its shares of common stock. In addition, Senseonics has granted the underwriter a 30-day option to purchase up to an additional $12 million of its shares of common stock. All of the shares to be sold in the offering a

Jun 25, 2018 08:50 am ET

Senseonics Launches the “Ever Mobile Clinic” – A Converted 18 Wheeler Training Facility to Tour United States

Senseonics Holdings, Inc. (NYSE American: SENS) today announced the launch of the company’s Ever Mobile Clinic Tour, a program to bring hands-on diabetes device training and education directly to U.S. patients and healthcare professionals in their local areas via a custom-built 18-wheeler mobile training facility.

Jun 25, 2018 08:38 am ET

Six-Month Data on Long-Term Eversense CGM System Show Sustained Accuracy in Longest Pediatric Continuous Sensor Study

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced the presentation by third party researchers of new data from a clinical study evaluating the performance of the Eversense® XL Continuous Glucose Monitoring (CGM) system for up to 180 days in pediatrics and adults with diabetes. Findings were presented on June 22, 2018 at the

You are here

Senseonics Holdings Inc (A:SENS)

Business Focus: Medical Equipment, Supplies & Distribution